Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD 8931

Known as: AZD-8931, AZD8931 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

QuinazolinesSapitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
Summary Background A substantial change in trial methodology for solid tumours has taken place, in response to increased… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2016
2016
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast…
PurposeAZD8931 is an orally bioavailable, reversible tyrosine kinase inhibitor of EGFR, HER2, and HER3 signaling. The Phase II… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2014
2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance
Modest up-regulation of either HER-ligands or receptors has been implicated in acquired endocrine resistance. AZD8931, a dual… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling
Fibroblasts in the tumour stroma (cancer-associated fibroblasts) influence tumour progression and response to therapeutics… Expand
  • figure 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2014
Review
2014
Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
HER2 (human epidermal growth factor receptor 2)-targeted therapy in breast cancer is one of the earliest and arguably most… Expand
2014
2014
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
IntroductionEpidermal growth factor receptor (EGFR) overexpression has been associated with prognostic and predictive value in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
SummaryAim AZD8931 is an oral equipotent inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling. This Phase I, open… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2013
2013
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
Deregulation of HER family signaling promotes proliferation and tumor cell survival and has been described in many human cancers… Expand
2013
2013
Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).
531 Background: Preclinical data suggest a key role for EGFR inhibition in delaying acquired resistance to ET in ER+ breast… Expand
Highly Cited
2010
Highly Cited
2010
AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE